IPF Ofev denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for ipf ofev are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Issue a "Not FDA-Approved" Denial for Ofev (nintedanib) in IPF

This denial occurs when Cigna's claim-editing system cannot match the submitted diagnosis code or the specific indication on the claim to its internal record of Ofev's FDA-approved uses. It can also appear when an outdated policy template is applied, or when the claim is coded in a way that makes the use appear off-label even though the prescribed use is squarely within the FDA-approved indication for idiopathic pulmonary fibrosis. Like the experimental denial, this is one of the most straightforwardly reversible denial types when the underlying use is genuinely on-label.

## Why This Denial Is Appealable

Ofev holds FDA approval for IPF. A denial claiming the drug is not FDA-approved for the submitted indication is either a coding mismatch or an application of a policy that does not reflect the current regulatory status of the drug. Both are correctable on appeal. The appeal record needs to clearly link the patient's confirmed IPF diagnosis to the FDA-approved labeling.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline printed on your Explanation of Benefits. Include the FDA-approval information and the prescriber's letter as primary exhibits. Cigna must decide within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719): If the internal appeal is denied, request independent external review. The reviewer will apply objective FDA approval standards and is not bound by Cigna's internal policy. The request window is generally up to four months from the denial notice.
• ERISA §503: Employer-sponsored plan members are entitled to a full-and-fair review and may access all documents Cigna relied on to issue the denial.
• Expedited review: Request simultaneously with every level of appeal if your prescriber certifies that a standard-timeline review would jeopardize your health.

## Documentation to Gather

1. FDA-approved prescribing information — The prescriber's letter should reference the current FDA-approved prescribing label for Ofev and confirm that the patient's diagnosis and use are consistent with that label. Direct Cigna to the label for exact indication language. 2. Diagnosis confirmation — Pulmonologist or specialist records with an ICD-coded IPF diagnosis supported by HRCT findings and pulmonary function test results. 3. On-label use attestation — Prescriber explicitly states the prescribed indication, confirms it matches the FDA-approved labeling, and provides the diagnosis code used on the claim. 4. Coding clarification — If there is a diagnosis-code mismatch, a corrected claim or a letter from the prescriber's billing department clarifying the intended code can resolve the technical trigger. 5. Applicable guideline reference — Prescriber may reference the relevant professional guideline organization (e.g., ATS/ERS) for IPF management to reinforce the standard-of-care basis.

## Criteria-Mapping Structure

Obtain the specific Cigna denial rationale from the Explanation of Benefits or the denial letter — it will identify the exact policy basis. Then address each stated criterion:

• FDA approval status for the claimed indication — link to the prescribing label
• Diagnosis code alignment with the approved indication — provide corrected or clarified coding if needed
• Prescriber specialty and clinical rationale
• Absence of off-label elements in the treatment plan

A one-page cover letter that walks Cigna's reviewer through the FDA label reference, the diagnosis documentation, and the coding clarification is usually sufficient to overturn this denial at the internal appeal level.